Leerink Partners analyst Daina Graybosch has maintained their bullish stance on BNTX stock, giving a Buy rating on August 14.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daina Graybosch has given her Buy rating due to a combination of factors related to BioNTech SE’s promising developments in their clinical trials. The initial results from the global Phase 2 dose optimization study of pumitamig (BNT327) in first-line extensive stage small cell lung cancer (ES-SCLC) have shown encouraging outcomes. These results align with those from a similar Chinese trial, which is significant given the potential differences in patient prognosis between the trials.
Moreover, the outcomes of pumitamig combined with chemotherapy compare favorably to existing global benchmark studies, such as the Phase 3 IMpower-133 study. However, Graybosch notes that while the overall response rate is promising, it alone is not enough to confirm the drug’s efficacy globally. She anticipates further confirmation through a larger patient sample and additional outcomes like response durability and progression-free survival, which will be presented at the World Conference on Lung Cancer. This potential for broader confirmation underpins her optimistic outlook on BioNTech’s stock.
According to TipRanks, Graybosch is an analyst with an average return of -13.6% and a 35.60% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Summit Therapeutics, and BioNTech SE.
In another report released on August 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $136.00 price target.